Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

ALDER BIOPHARMACEUTICALS INC

Form 4

January 06, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

OMB APPROVAL

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

burden hours per response... 0.5

Estimated average

See Instruction

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person * Litton Mark James

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Symbol

ALDER BIOPHARMACEUTICALS

(Check all applicable)

INC [ALDR]

(Middle) (First)

3. Date of Earliest Transaction

Director 10% Owner _X__ Officer (give title Other (specify

(Month/Day/Year)

below)

Chief Business Officer

11804 NORTH CREEK PARKWAY 01/04/2016 **SOUTH**

6. Individual or Joint/Group Filing(Check Applicable Line)

(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

Issuer

BOTHELL, WA 98011

(City)	(State)	(Zip) Tak	ole I - Non-	-Derivative	e Secu	rities Acqui	red, Disposed of,	or Beneficial	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	oror Dispos (Instr. 3, 4	(A) or	5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/04/2016		Code V M	Amount 25,000 (1)	(D)	Price \$ 0.385	98,718 <u>(2)</u>	D	
Common Stock	01/04/2016		S	17,291 (3)	D	\$ 31.1942 (4)	81,427	D	
Common Stock	01/04/2016		S	7,709 (3)	D	\$ 31.8553 (5)	73,718	D	
Common Stock							30,000	I	Held in trust for

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

		the benefit
		of Reporting
		Person's
		minor
		child
		Held in
		trust for
Common		the benefit of
Common Stock	30,000 I	Reporting
Stock		Person's
		minor
		child
		Held in
		trust for
Common		the benefit of
Stock	30,000 I	Reporting
		Person's
		minor
		child
Reminder: Report on a separate line for each class of securities bene	ficially owned directly or indirectly.	
	Persons who respond to the collection of	SEC 1474
	information contained in this form are not required to respond unless the form	(9-02)
	displays a currently valid OMB control number.	
	quired, Disposed of, or Beneficially Owned s, options, convertible securities)	
1. Title of 2. 3. Transaction Date 3A. Deemed	4. 5. Number of 6. Date Exercisable and	7. Title and Amount of 8
Derivative Conversion (Month/Day/Year) Execution Date, if	TransactionDerivative Expiration Date	Underlying Securities D
Security or Exercise any (Instr. 3) Price of (Month/Day/Year)	Code Securities (Month/Day/Year) (Instr. 8) Acquired (A)	(Instr. 3 and 4) S
Derivative	or Disposed of	`
Security	(D) (Instr. 3, 4,	
	and 5)	
		Amount

Code V (A)

 \mathbf{M}

Stock Option

Buy)

(Right to

\$ 0.385

01/04/2016

Date

(D)

25,000

Exercisable

(6)

Expiration

09/14/2016

Date

Title

Common

Stock

Number

of Shares

25,000

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Litton Mark James 11804 NORTH CREEK PARKWAY SOUTH BOTHELL, WA 98011

Chief Business Officer

Signatures

/s/ Mark J. 01/06/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2015.
- (2) Includes 799 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2015.
- (3) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2015.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$30.60 to \$31.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.60 to \$32.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.
- **(6)** The option is fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3